---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092262"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:38:48.891162+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# EyePoint reports Q2 net loss of $30.8M; cash runway through DURAVYU Phase 3 topline in 2026

## Summary
- Net loss $30.8M ($0.58/sh) vs $22.9M loss ($0.61/sh) in Q2 2023; total net revenue $9.5M.
- Cash and investments $280.2M at June 30, 2024; expected to fund operations through Phase 3 wet AMD topline data in 2026.
- Phase 3 LUGANO wet AMD trial on track for first patient dosing in 2024; LUCIA trial to follow shortly.
- Positive 12-month DAVIO 2 data: DURAVYU non-inferior to aflibercept in visual acuity; majority supplement-free.
- Phase 2 VERONA (DME) fully enrolled; topline data anticipated Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-092262
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024092262/0000950170-24-092262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024092262/eypt-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092262
- JSON: https://secwatch.observer/filing/0000950170-24-092262.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.